



## PhaseBio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

September 9, 2020

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Sep. 9, 2020-- [PhaseBio Pharmaceuticals, Inc.](#) (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the upcoming H.C. Wainwright 22<sup>nd</sup> Annual Global Investment Conference on Tuesday, September 15, at 12:00 p.m. EDT.

The event will be available via live webcast from the "Events and Presentations" page of the "Investors" section of the company's website at [www.phasebio.com](http://www.phasebio.com). The webcast replay will be available for 90 days after the conclusion of the live presentation.

### About PhaseBio

[PhaseBio Pharmaceuticals, Inc.](#) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company's pipeline includes: PB2452, a novel reversal agent for the antiplatelet therapy ticagrelor; PB1046, a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension and hospitalized COVID-19 patients at high risk for rapid clinical deterioration and ARDS; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio's proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including PB1046, and drives both internal and partnership drug-development opportunities.

PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit [www.phasebio.com](http://www.phasebio.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200909006016/en/): <https://www.businesswire.com/news/home/20200909006016/en/>

### Investor Contact:

John Sharp  
PhaseBio Pharmaceuticals, Inc.  
Chief Financial Officer  
(610) 981-6506  
[john.sharp@phasebio.com](mailto:john.sharp@phasebio.com)

### Media Contact:

Will Zasadny  
Canale Communications, Inc.  
[will@canalecomm.com](mailto:will@canalecomm.com)  
619-961-8848

Source: PhaseBio Pharmaceuticals, Inc.